TEAD Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
TEAD Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy was generated using PatSnap Life Sciences MCP Servers. Target & Disease MCP contributed the biology and disease context, while Clinical Trials MCP contributed validation evidence and clinical competition signals.
Why this report exists: it shows how AI agents can use PatSnap MCP data to produce target evaluation workflows covering biology, validation, competition, IP, and R&D recommendation. Explore PatSnap Life Sciences MCP Servers for AI agents.
Executive Summary
This TEAD Target Evaluation Report is generated from PatSnap MCP data. TEAD is an emerging Hippo pathway transcription-factor target, with early clinical activity in selected advanced solid tumors, mesothelioma-enriched populations, and NF2-mutant settings.
Target
TEAD family
UniProt TEAD family
Drug Count
93
83 development-stage assets
Trials
23
TEAD solid-tumor trials retrieved by Clinical Trials MCP
Results
8
Clinical Trials MCP result records
Target Attractiveness Snapshot
Biology
Target & Disease MCP maps TEAD as the TEA-domain transcription-factor family, the transcriptional output node of YAP/TAZ-Hippo pathway biology.
Disease Context
Clinical interest centers on mesothelioma, NF2-mutant tumors, and solid tumors where YAP/TAZ transcriptional dependency is high.
Strategy
Develop TEAD programs around Hippo-pathway biomarkers, NF2 status, palmitoylation-pocket differentiation, and tolerability.
Overall Target Evaluation Score: 75/100
- Biology: Transcriptional dependency biology is compelling but target-family biology is complex.
- Clinical validation: Clinical Trials MCP returned 23 TEAD solid-tumor trials and 8 result records.
- Competition: Competition is early but active with ODM-212, VT3989, IK-930 and ISM6331.
- White space: White space remains in TEAD isoform selectivity and biomarker-defined tumor types.
Biology and Disease Rationale
TEAD transcription factors mediate YAP/TAZ-driven transcription. Because TEAD is a family target, clinical reports often use TEAD or YAP/TEAD language rather than TEAD1 alone; Clinical Trials MCP confirmed that TEAD1-specific mesothelioma search was sparse but TEAD-family solid-tumor records are active.
Clinical Trials MCP returned ODM-212 TEADES and TEADCO studies, TYK-01054, ISM6331 in advanced/metastatic malignant mesothelioma or other solid tumors, and result records for VT3989, IK-930, ODM-212 and verteporfin PDT concepts.
Explore PatSnap Life Sciences MCP Servers for AI agents
Validation and Clinical Competition
| First-in-human activity | ODM-212 first-in-human TEADES records were indexed as positive in advanced solid tumors. |
| Mesothelioma/NF2 strategy | VT3989 records focus on malignant mesothelioma and NF2-mutant enriched tumors. |
| Pipeline breadth | IK-930 positive dose-escalation data and ISM6331 recruitment indicate multiple entrants. |
| Family-query caveat | TEAD1-specific mesothelioma returned no trials, so the report uses TEAD-family clinical evidence. |
IP and Competitive Strategy
TEAD IP should examine palmitoylation-pocket binders, TEAD isoform selectivity, YAP/TAZ disruption, NF2 or Hippo biomarkers, mesothelioma claims, and transcription-factor druggability methods.
Recommendation
TEAD is a promising emerging oncology target. The best programs will define the right Hippo-pathway patient segment and show that their TEAD-family profile improves efficacy or tolerability.
Bottom line: This TEAD Target Evaluation Report is generated from PatSnap MCP data. TEAD is an emerging Hippo pathway transcription-factor target, with early clinical activity in selected advanced solid tumors, mesothelioma-enriched populations, and NF2-mutant settings.
Start building target evaluation agents with PatSnap Life Sciences MCP Servers
